Connect with us
  • Elysium

Premium content

Coya Therapeutics advances towards approval for ALS trials



Coya Therapeutics has further advanced towards clinical trials on its potential therapy for the treatment of amyotrophic lateral sclerosis (ALS).

The company announced that it has held successful pre-IND (Investigational New Drug) and Type C meetings with the US Food and Drug Administration (FDA).

Read this and more exclusive content every day as an NR Times online subscriber. Just £2.99 a month, cancel anytime.

Login Join Now